Mohamed Azab

1.1k total citations
33 papers, 757 citations indexed

About

Mohamed Azab is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mohamed Azab has authored 33 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 8 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mohamed Azab's work include Testicular diseases and treatments (4 papers), Chemotherapy-induced organ toxicity mitigation (3 papers) and Gestational Trophoblastic Disease Studies (3 papers). Mohamed Azab is often cited by papers focused on Testicular diseases and treatments (4 papers), Chemotherapy-induced organ toxicity mitigation (3 papers) and Gestational Trophoblastic Disease Studies (3 papers). Mohamed Azab collaborates with scholars based in France, United States and Egypt. Mohamed Azab's co-authors include Bernard Paule, Éric Pujade-Lauraine, Jean Pierre Droz, Michel Marty, Suzy Scholl, P Pouillart, J Bons, Christine Théodore, Jean‐Pierre Droz and Marcel Hayat and has published in prestigious journals such as New England Journal of Medicine, Cancer and Annals of Oncology.

In The Last Decade

Mohamed Azab

29 papers receiving 722 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohamed Azab France 12 358 167 146 131 114 33 757
Matthew J. Selleck United States 11 182 0.5× 64 0.4× 183 1.3× 18 0.1× 113 1.0× 25 666
Yusaku Tazawa Japan 17 407 1.1× 40 0.2× 152 1.0× 346 2.6× 45 0.4× 63 1.2k
Gul Bano United Kingdom 14 166 0.5× 87 0.5× 63 0.4× 69 0.5× 191 1.7× 43 773
Janet B. Arrowsmith United States 6 250 0.7× 31 0.2× 85 0.6× 28 0.2× 77 0.7× 6 726
M J Gaspar Spain 13 95 0.3× 29 0.2× 81 0.6× 84 0.6× 61 0.5× 34 534
C.L.H. van Berlo Netherlands 17 180 0.5× 105 0.6× 203 1.4× 25 0.2× 31 0.3× 31 672
Lara Kovell United States 16 184 0.5× 72 0.4× 59 0.4× 81 0.6× 113 1.0× 64 1.0k
Sanambar Sadighi Iran 12 175 0.5× 57 0.3× 154 1.1× 29 0.2× 36 0.3× 53 492
Akihisa Hidaka Japan 15 156 0.4× 109 0.7× 198 1.4× 15 0.1× 57 0.5× 29 613

Countries citing papers authored by Mohamed Azab

Since Specialization
Citations

This map shows the geographic impact of Mohamed Azab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamed Azab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamed Azab more than expected).

Fields of papers citing papers by Mohamed Azab

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohamed Azab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamed Azab. The network helps show where Mohamed Azab may publish in the future.

Co-authorship network of co-authors of Mohamed Azab

This figure shows the co-authorship network connecting the top 25 collaborators of Mohamed Azab. A scholar is included among the top collaborators of Mohamed Azab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohamed Azab. Mohamed Azab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Azab, Mohamed, et al.. (2025). Robust authentication and key agreement protocol for smart microgrid environment. Journal of Information Security and Applications. 94. 104202–104202.
2.
Azab, Mohamed, et al.. (2024). Multilingual Standalone Trustworthy Voice-Based Social Network for Disaster Situations. 264–270. 2 indexed citations
3.
Azab, Mohamed, et al.. (2023). Role of Rhizobium leguminosarum In Mitigating the Inhibitory Effects of Water Deficit on Arachis hypogaea. 15(1). 87–103. 2 indexed citations
4.
Azab, Mohamed, et al.. (2019). Safety of endoscopic retrograde cholangiopancreatography (ERCP) in pregnancy: A systematic review and meta-analysis. Saudi Journal of Gastroenterology. 25(6). 341–341. 21 indexed citations
5.
6.
Mashiana, Harmeet S., et al.. (2017). Safety of ERCP in Elderly Patients: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology. 112. S471–S472. 1 indexed citations
7.
Gross, Cole D., et al.. (2017). Spontaneous pneumomediastinum: A rare complication of methamphetamine use. Respiratory Medicine Case Reports. 21. 25–26. 5 indexed citations
8.
Yamashita, Takashi, et al.. (2017). Effects of the 2009 Medical Cannabinoid Legalization Policy on Hospital Use for Cannabinoid Dependency and Persistent Vomiting. Clinical Gastroenterology and Hepatology. 15(12). 1876–1881. 19 indexed citations
9.
Azab, Mohamed, et al.. (2011). Radiofrequency ablation combined with percutaneous ethanol injection in patients with hepatocellular carcinoma. Arab Journal of Gastroenterology. 12(3). 113–118. 25 indexed citations
10.
Gore, Martin, Helena Earl, Martin Tattersall, et al.. (1995). A phase II study of Tomudex in relapsed epithelial ovarian cancer. Annals of Oncology. 6(7). 724–725. 9 indexed citations
11.
Kattan, Joseph, M. Durand, Jean‐Pierre Droz, et al.. (1994). Phase I Study of Retelliptine Dihydrochloride (SR 95325 B) Using a Single Two-Hour Intravenous Infusion Schedule. American Journal of Clinical Oncology. 17(3). 242–245. 14 indexed citations
12.
Rouëssé, Jacques, et al.. (1993). Phase II study of elliptinium acetate salvage treatment of advanced breast cancer. European Journal of Cancer. 29(6). 856–859. 43 indexed citations
13.
Khayat, D., et al.. (1992). Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion. Cancer Chemotherapy and Pharmacology. 30(3). 226–228. 10 indexed citations
14.
Kattan, Joseph, Jean‐Pierre Droz, Vincent Ribrag, et al.. (1992). Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients. European Journal of Cancer. 28(4-5). 867–870. 4 indexed citations
15.
Mahjoubi, M., et al.. (1990). Phase II Trial of Ifosfamide in the Treatment of Metastatic Hormone-Refractory Patients with Prostatic Cancer. Cancer Investigation. 8(5). 477–481. 11 indexed citations
16.
Marty, Michel, P Pouillart, Suzy Scholl, et al.. (1990). Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis. New England Journal of Medicine. 322(12). 816–821. 328 indexed citations
17.
Ribrag, Vincent, Droz Jp, Carole Bouleuc, et al.. (1990). [Salvage chemotherapy of non-seminomatous germ cell tumors. Phase II trial of a combination of etoposide, ifosfamide and high-dose cisplatin].. PubMed. 19(27). 1263–6. 1 indexed citations
18.
Jp, Droz, Mario Ghosn, C Théodore, et al.. (1989). Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumors.. PubMed. 303. 739–47. 3 indexed citations
19.
Théodore, Christine, Mohamed Azab, Jean‐Pierre Droz, et al.. (1989). Treatment of high-risk gestational trophoblastic disease with chemotherapy combinations containing cisplatin and etoposide. Cancer. 64(9). 1824–1828. 33 indexed citations
20.
Azab, Mohamed, Christine Théodore, Jean‐Pierre Droz, et al.. (1988). Prognostic factors in gestational trophoblastic tumors. A multivariate analysis. Cancer. 62(3). 585–592. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew J. Selleck Breakdown of academic impact, for papers by Yusaku Tazawa Breakdown of academic impact, for papers by Gul Bano Breakdown of academic impact, for papers by Janet B. Arrowsmith Breakdown of academic impact, for papers by M J Gaspar Breakdown of academic impact, for papers by C.L.H. van Berlo Breakdown of academic impact, for papers by Lara Kovell Breakdown of academic impact, for papers by Sanambar Sadighi Breakdown of academic impact, for papers by Akihisa Hidaka
Rankless by CCL
2026